CLAIM AMENDMENTS

Claims 1 through 70 (canceled)

71. (New) A liquid crystal gel for use in the manufacture of transdermal pharmaceutical compositions and healing cosmetics, which comprises:

Polyoxyethylene-glyceryl-trioleate	26.7 - 40.0 %,
Propylene-glycol	13.3 - 20.0 %,
Isopropyl myristate	5.0 - 35.0 %,
Ethanol	0.01 - 10.0 %
Benzyl alcohol	0.5 - 1.5 %,
a hyaluronic acid salt or complex	0.01 - 2.00 %, and
Purified water	12.5 to 26.5%

72. (New) The liquid crystal gel defined in claim 71 wherein the hyaluronic acid salt or complex is sodium hyaluronate.

73. (New) The liquid crystal gel defined in claim 71 wherein the hyaluronic acid salt or complex is zinc hyaluronic acid complex.

74. (New) The liquid crystal gel defined in claim 71 wherein the ratio of polyoxyethylene-glyceryl-trioleate and propylene-glycol is 2:1.

75. (New) The liquid crystal gel defined in claim 71 which comprises:

Polyoxyethylene-glyceryl-trioleate	30.0 - 35.0 %,
Propylene-glycol	15.0 - 18.0 %,
Isopropyl myristate	17.0 - 20.0 %,
Ethanol	4.0 - 6.0 %
Benzyl alcohol	0.7 - 1.3 %,
a hyaluronic acid salt or complex	0.05 - 0.15 %, and
Purified water	20.0 to 25.0%

76. (New) The liquid crystal gel defined in claim 75 wherein the hyaluronic acid salt or complex is sodium hyaluronate having a mean molecular weight from 580,000 to 620,000 or from 1,350,000 to 1,400,000.

77. (New) The liquid crystal gel defined in claim 75 wherein the hyaluronic acid salt or complex is zinc hyaluronic acid complex having a mean molecular weight from 600,000 to 650,000..

78. (New) The liquid crystal gel defined in claim 76 which comprises:

Polyoxyethylene-glyceryl-trioleate	33.3 %,
Propylene-glycol	16.7 %,
Isopropyl myristate	19.0 %,
Ethanol	5.0 %

Benzyl alcohol	1.0%,
Sodium hyaluronate	0.1 %, and
Supplemented with purified water ad	100% .

79. (New) The liquid crystal gel defined in claim 77 which comprises:

Polyoxyethylene-glyceryl-trioleate	33.3 %,
Propylene-glycol	16.7 %,
Isopropyl myristate	19.0 %,
Ethanol	5.0 %
Benzyl alcohol	1.0%,
Zinc hyaluronic acid complex	0.1 %, and
Supplemented with purified water ad	100%

80. (new) A transdermal pharmaceutical composition as a liquid crystal gel, which consists essentially of:

(a) an estrogen component; and

(b) a progestin component, as therapeutically effective ingredients wherein said estrogen component and said progestin component are included in a therapeutically effective amount sufficient for hormone replacement therapy; and

(c) a liquid crystal gel which contains the therapeutically active ingredients, said liquid crystal gel consisting essentially of:

Polyoxyethylene-glyceryl-trioleate	26.7 - 40.0 %,
Propylene-glycol	13.3 - 20.0 %,

Isopropyl myristate	5.0 - 35.0 %,
Ethanol	0.01 - 10.0 %
Benzyl alcohol	0.5 - 1.5 %,
a hyaluronic acid salt or complex	0.01 - 2.00 %, and
Purified water	12.5 to 26.5%

81. (New) The transdermal pharmaceutical composition as a liquid crystal gel defined in claim 80 wherein the estrogen component is estradiol.

82. (New) The transdermal pharmaceutical composition as a liquid crystal gel defined in claim 80 wherein the progestin compound is gestodene.

83. (New) The transdermal pharmaceutical composition as a liquid crystal gel defined in claim 80 wherein the progestin compound is etonogestrel.

84. (New) The transdermal pharmaceutical composition as a liquid crystal gel defined in claim 80 wherein the progestin compound is levonorgestrel.

85. (New) A method of treating a patient for moderate to severe vasomotor symptoms, as well as hot flashes, nocturnal sweating, and palpitation due to post-menopausal estrogen

deficiency, which comprises the step of transdermally administering to the skin of the patient, a therapeutically effective amount of the transdermal pharmaceutical composition defined in claim 80.

86. (New) A transdermal pharmaceutical composition as a liquid crystal gel, which consists essentially of:

(a) at least one therapeutically active ingredient and

(b) a liquid crystal gel which contains the at least one therapeutically active ingredient, said liquid crystal gel consisting essentially of:

Polyoxyethylene-glyceryl-trioleate	26.7 - 40.0 %,
Propylene-glycol	13.3 - 20.0 %,
Isopropyl myristate	5.0 - 35.0 %,
Ethanol	0.01 - 10.0 %
Benzyl alcohol	0.5 - 1.5 %,
a hyaluronic acid salt or complex	0.01 - 2.00 %, and
Purified water	12.5 to 26.5% .

87. (New) The transdermal pharmaceutical composition as a liquid crystal gel defined in claim 86 wherein the therapeutically active ingredient is ondansetron.

88. (New) The transdermal pharmaceutical composition as a liquid crystal gel defined in claim 86 wherein the therapeutically active ingredient is terbinafine.

89. (New) The transdermal pharmaceutical composition as a liquid crystal gel defined in claim 86 wherein the therapeutically active ingredient is fluconazole.

90. (New) The transdermal pharmaceutical composition as a liquid crystal gel defined in claim 86 wherein the therapeutically active ingredient is metronidazole.

91. (New) The transdermal pharmaceutical composition as a liquid crystal gel defined in claim 86 wherein the therapeutically active ingredient is fentanyl.

92. (New) The transdermal pharmaceutical composition as a liquid crystal gel defined in claim 86 wherein the therapeutically active ingredient is nandrolone decanoate.

93. (New) The transdermal pharmaceutical composition as a liquid crystal gel defined in claim 86 wherein the therapeutically active ingredient is nestorone.

94. (New) The transdermal pharmaceutical composition as a liquid crystal gel defined in claim 86 wherein the therapeutically active ingredient is norethisterone.

95. (New) The transdermal pharmaceutical composition as a liquid crystal gel defined in claim 86 wherein the therapeutically active ingredient is eperisone.

96. (New) The transdermal pharmaceutical composition as a liquid crystal gel defined in claim 86 wherein the therapeutically active ingredient is tolperisone.

97. (New) The transdermal pharmaceutical composition as a liquid crystal gel defined in claim 86 wherein the therapeutically active ingredient is vinpocetine.

98. (New) The transdermal pharmaceutical composition as a liquid crystal gel defined in claim 86 wherein the therapeutically active ingredient is ketamine.

99. (New) The transdermal pharmaceutical composition as a liquid crystal gel defined in claim 86 wherein the therapeutically active ingredient is vincristine.

100. (New) The transdermal pharmaceutical composition as a liquid crystal gel defined in claim 86 wherein the therapeutically active ingredient is vinblastine.